Logo image
Perioperative genitourinary infection associated with sodium-glucose co-transporter 2 inhibitor use
Report   Open access

Perioperative genitourinary infection associated with sodium-glucose co-transporter 2 inhibitor use

Stephen Melnick, Priya Rajagopalan, Theresa Lynn and Anthony Donato
Journal of Community Hospital Internal Medicine Perspectives, v 8(5), pp 315-316
03 Sep 2018
PMID: 30357044
url
https://doi.org/10.1080/20009666.2018.1527667View
Published, Version of Record (VoR) Open

Abstract

genitourinary infections SGLT2 inhibitor Sodium glucose co-transporter inhibitor
Context: Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are a novel treatment approved for type 2 diabetes mellitus to lower hyperglycemia, systolic blood pressure, and promote weight loss. Commonly reported serious adverse events include increased mycotic urogenital infections, orthostatic hypotension, and normoglycemic ketoacidosis. Case report: We present a case of a 47-year old man with a history of type 2 diabetes mellitus initiated on the SGLT-2 inhibitor canagliflozin preoperatively before a penile implant, who presented with late postoperative MRSA bacteremia and scrotal abscess requiring implant extraction. Conclusion: As the SGLT-2 inhibitors are gaining in popularity, prescribers must be aware of the potential adverse genitourinary infectious outcomes. Providers should use caution and avoid initiating SGLT-2 inhibitors in the perioperative setting, and may even consider holding or discontinuing this medication in the setting of impending GU surgery.

Metrics

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Endocrinology & Metabolism
Logo image